Background Triple-negative breast cancer is an aggressive breast cancer subtype characterized by the absence of human epidermal growth factor receptor 2, estrogen and progesterone receptors, limiting targeted therapy options. Cisplatin, a chemotherapeutic agent, induces DNA damage and exhibits some efficacy against triple-negative breast cancer, but its effectiveness is often reduced by chemoresistance and systemic toxicity.Results To optimize this strategy in a biocompatible and precise manner, we developed a nanoplatform based on red blood cell-derived extracellular vesicles for the combined delivery of Cetuximab and cisplatin, enabling immune evasion, and the possibility of autologous personalization and GMP-compliant production. Owing to their DNA-free lumen and lack of EGFR, RBC-EVs preserve cisplatin activity and prevent interference with cetuximab. This formulation enhances cisplatin's cytotoxicity by up to 50%, as shown in vitro and in patient-derived organoids. It effectively reduces chemoresistance by downregulating hypoxia-related genes and promoting ferroptosis, additionally, it improves cisplatin's cytotoxic effects while reducing hemotoxicity compared to the administration of free cisplatin.Conclusions These findings highlight the potential of red blood cell-derived extracellular vesicles as a biocompatible delivery system enabling combined therapy and offering a promising strategy to overcome current limitations in TNBC treatment.

Red blood cell-derived extracellular vesicles enable cisplatin and cetuximab combined therapy against triple-negative breast cancer / Romano, M., Musico, A., Tassoni, S., Paolini, L., Zendrini, A., Gilberti, E., Orlandi, F., Pedrazzi, T., Alacqua, S., Segala, A., Zenatelli, R., Cifola, I., Mangano, E., Consolandi, C., Camboni, T., Signati, L., Mazzucchelli, S., Neva, A., Ragni, M., Severgnini, M., et al.. - In: JOURNAL OF NANOBIOTECHNOLOGY. - ISSN 1477-3155. - 24:1(2026), pp. 1-29. [10.1186/s12951-026-04628-3]

Red blood cell-derived extracellular vesicles enable cisplatin and cetuximab combined therapy against triple-negative breast cancer

Pomarico G.;
2026

Abstract

Background Triple-negative breast cancer is an aggressive breast cancer subtype characterized by the absence of human epidermal growth factor receptor 2, estrogen and progesterone receptors, limiting targeted therapy options. Cisplatin, a chemotherapeutic agent, induces DNA damage and exhibits some efficacy against triple-negative breast cancer, but its effectiveness is often reduced by chemoresistance and systemic toxicity.Results To optimize this strategy in a biocompatible and precise manner, we developed a nanoplatform based on red blood cell-derived extracellular vesicles for the combined delivery of Cetuximab and cisplatin, enabling immune evasion, and the possibility of autologous personalization and GMP-compliant production. Owing to their DNA-free lumen and lack of EGFR, RBC-EVs preserve cisplatin activity and prevent interference with cetuximab. This formulation enhances cisplatin's cytotoxicity by up to 50%, as shown in vitro and in patient-derived organoids. It effectively reduces chemoresistance by downregulating hypoxia-related genes and promoting ferroptosis, additionally, it improves cisplatin's cytotoxic effects while reducing hemotoxicity compared to the administration of free cisplatin.Conclusions These findings highlight the potential of red blood cell-derived extracellular vesicles as a biocompatible delivery system enabling combined therapy and offering a promising strategy to overcome current limitations in TNBC treatment.
2026
Cetuximab; Cisplatin; Combined therapy; Extracellular vesicles; Red blood cells; Triple-negative breast cancer
01 Pubblicazione su rivista::01a Articolo in rivista
Red blood cell-derived extracellular vesicles enable cisplatin and cetuximab combined therapy against triple-negative breast cancer / Romano, M., Musico, A., Tassoni, S., Paolini, L., Zendrini, A., Gilberti, E., Orlandi, F., Pedrazzi, T., Alacqua, S., Segala, A., Zenatelli, R., Cifola, I., Mangano, E., Consolandi, C., Camboni, T., Signati, L., Mazzucchelli, S., Neva, A., Ragni, M., Severgnini, M., et al.. - In: JOURNAL OF NANOBIOTECHNOLOGY. - ISSN 1477-3155. - 24:1(2026), pp. 1-29. [10.1186/s12951-026-04628-3]
File allegati a questo prodotto
File Dimensione Formato  
Romano_Red-Blood_2026.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 5.86 MB
Formato Adobe PDF
5.86 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1773873
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact